UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 126

Sortiert nach

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

Journal of clinical oncology, 2012-05, Vol.30 (15), p.1796-1804

2012

Link zum Volltext

Verfügbarkeit prüfen

Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer

JNCI : Journal of the National Cancer Institute, 2014-10, Vol.106 (10), p.1

2014

Link zum Volltext

Verfügbarkeit prüfen

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

Clinical cancer research, 2011-03, Vol.17 (6), p.1591-1602

2011

Link zum Volltext

Verfügbarkeit prüfen

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

Cancer research (Chicago, Ill.), 2006-02, Vol.66 (3), p.1630-1639

2006

Link zum Volltext

Verfügbarkeit prüfen

Second-line dovitinib (TKI258) in patients with FGFR2 -mutated or FGFR2 -non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study

The lancet oncology, 2015-06, Vol.16 (6), p.686-694

2015

Link zum Volltext

Verfügbarkeit prüfen

Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study

Journal of clinical oncology, 2010-06, Vol.28 (17), p.2874-2880

2010

Link zum Volltext

Verfügbarkeit prüfen

Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma

Clinical cancer research, 2011-04, Vol.17 (8), p.2373-2384

2011

Link zum Volltext

Verfügbarkeit prüfen

Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures

Gynecologic oncology, 2016-04, Vol.141 (1), p.95-100

2016

Link zum Volltext

Verfügbarkeit prüfen

Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors

Diagnostic pathology, 2022-09, Vol.17 (1), p.70-70, Article 70

2022

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of PD-1 and VEGF in microsatellite-stable endometrial cancer

The lancet oncology, 2019-05, Vol.20 (5), p.612-614

Konecny, Gottfried E

2019

Link zum Volltext

Verfügbarkeit prüfen

Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

Gynecologic oncology reports, 2023-06, Vol.47, p.101155-101155, Article 101155

2023

Link zum Volltext

Verfügbarkeit prüfen

Intensive Dose-Dense Compared With Conventionally Scheduled Preoperative Chemotherapy for High-Risk Primary Breast Cancer

Journal of clinical oncology, 2009-06, Vol.27 (18), p.2938-2945

2009

Link zum Volltext

Verfügbarkeit prüfen

Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells

Molecular cancer therapeutics, 2013-05, Vol.12 (5), p.632-642

2013

Link zum Volltext

Verfügbarkeit prüfen

Current and future role of neoadjuvant therapy for breast cancer

Breast (Edinburgh), 2014-10, Vol.23 (5), p.526-537

2014

Link zum Volltext

Verfügbarkeit prüfen

Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas

The Journal of pathology, 2010-04, Vol.220 (5), p.551-561

2010

Link zum Volltext

Verfügbarkeit prüfen

Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients

Clinical cancer research, 2004-03, Vol.10 (5), p.1706-1716

2004

Link zum Volltext

Verfügbarkeit prüfen

Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer

International journal of molecular sciences, 2013-02, Vol.14 (2), p.3094-3109

2013

Link zum Volltext

Verfügbarkeit prüfen

Gene-expression signatures in ovarian cancer: Promise and challenges for patient stratification

Gynecologic oncology, 2016-05, Vol.141 (2), p.379-385

2016

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes

G3 : genes - genomes - genetics, 2016-12, Vol.6 (12), p.4097-4103

2016

Link zum Volltext

Verfügbarkeit prüfen

Cyclin-dependent kinase pathways as targets for women's cancer treatment

Current opinion in obstetrics & gynecology, 2016-02, Vol.28 (1), p.42-48

Konecny, Gottfried E

2016

Link zum Volltext

Verfügbarkeit prüfen

Understanding Exceptional Responses to Poly (ADP-ribose) Polymerase Inhibition in Sporadic Ovarian Cancer

Journal of clinical oncology, 2017-04, Vol.35 (11), p.1151-1153

Konecny, Gottfried E

2017

Link zum Volltext

Verfügbarkeit prüfen

Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors

The cancer journal (Sudbury, Mass.), 2021-11, Vol.27 (6), p.482

2021

Link zum Volltext

Verfügbarkeit prüfen

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

The lancet oncology, 2017, Vol.18 (1), p.75-87

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 126

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(124)
Mit Volltextzugriff
(117)

Publikationsform

Sprache

Englisch
(126)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

Second-line dovitinib (TKI258) in patients with FGFR2 -mutated or FGFR2 -non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study

Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study

Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma

Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures

Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors

Inhibition of PD-1 and VEGF in microsatellite-stable endometrial cancer

Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

Intensive Dose-Dense Compared With Conventionally Scheduled Preoperative Chemotherapy for High-Risk Primary Breast Cancer

Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells

Current and future role of neoadjuvant therapy for breast cancer

Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas

Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients

Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer

Gene-expression signatures in ovarian cancer: Promise and challenges for patient stratification

Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes

Cyclin-dependent kinase pathways as targets for women's cancer treatment

Understanding Exceptional Responses to Poly (ADP-ribose) Polymerase Inhibition in Sporadic Ovarian Cancer

Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

Suchergebnisse filtern